Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)
A Single-center Phase 2 Study of Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
Sponsor: The First Hospital of Jilin University
This PHASE2 trial investigates IIIA Stage Non-small Cell Lung Cancer and is currently ongoing. The First Hospital of Jilin University leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jul 2023 — Nov 2023 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Feb 2023 — Jul 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Oct 2021 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Hospital of Jilin University
For direct contact, visit the study record on ClinicalTrials.gov .